Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Pieris Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
PIRS
Nasdaq
8731
https://www.pieris.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Pieris Pharmaceuticals Inc
Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential
- Mar 27th, 2024 12:00 pm
Investors Don't See Light At End Of Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Tunnel And Push Stock Down 27%
- Dec 18th, 2023 10:23 am
Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?
- Nov 19th, 2023 1:10 pm
Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's Why
- Sep 25th, 2023 4:00 pm
Is Pieris Pharmaceuticals (PIRS) a Value Trap? A Comprehensive Analysis
- Aug 24th, 2023 4:32 pm
Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's What You Should Know
- Aug 23rd, 2023 4:00 pm
Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
- Aug 17th, 2023 12:00 pm
Pieris (PIRS) Pursues Strategic Alternatives, Stock Rises
- Jul 19th, 2023 12:40 pm
Why Pieris Pharmaceuticals Shares Shooting Higher Today?
- Jul 18th, 2023 5:59 pm
Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring
- Jul 18th, 2023 1:15 pm
3 Doomed Biotech Stocks Destined for Disaster
- Jul 17th, 2023 11:29 am
Pieris (PIRS) Declines as AZN Halts Study of Asthma Candidate
- Jun 23rd, 2023 2:50 pm
Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study
- Jun 21st, 2023 11:00 am
We're A Little Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
- Jun 11th, 2023 2:28 pm
Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference
- Jun 2nd, 2023 8:30 pm
Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference
- May 22nd, 2023 12:00 pm
Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference
- May 21st, 2023 12:00 pm
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Analysts Just Cut Their EPS Forecasts Substantially
- May 15th, 2023 10:07 am
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q1 2023 Earnings Call Transcript
- May 11th, 2023 5:41 pm
Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Lags Revenue Estimates
- May 10th, 2023 12:15 pm
Scroll